Drug Details

General Information of the Drug (ID: DR5893)
Name
Bezafibrate
Synonyms
bezafibrate; 41859-67-0; Bezalip; Cedur; Bezafibrat; Befizal; Sklerofibrat; Azufibrat; Bezatol; Bezafibratum; Bezafibrato; Bezafibratum [INN-Latin]; Bezafibrato [INN-Spanish]; Bezatol SR (TN); BM-15.075; UNII-Y9449Q51XH; Difaterol; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; BM 15.075; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; BM-15075; MLS000028533; CHEMBL264374; durabezur; Reducterol; Bezabeta; Bezacur; Bezamerck; Eulitop; Solibay; CHEBI:47612; Lipox; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; Bezafibrat PB; Y9449Q51XH; Beza-Lande; Beza-Puren; Regadrin B; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-; MFCD00078970; BM15075; NCGC00016850-01; SMR000058298; Bezafibrato [Spanish]; Bezalip Retard; CAS-41859-67-0; DSSTox_CID_9869; Propionic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; DSSTox_RID_78826; DSSTox_GSID_29869; 2-(4-(2-(4-Chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid; 2-{4-[2-(4-chlorobenzamido)ethyl]phenoxy}-2-methylpropanoic acid; BM 15075; LO 44; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(4-{2-[(4-chlorophenyl)formamido]ethyl}phenoxy)-2-methylpropanoic acid; 2-[P-[2-P-CHLOROBENZAMIDO)ETHYL]PHENOXY]-2-METHYLPROPIONIC ACID; BF-759; CCRIS 9085; SR-01000000106; EINECS 255-567-9; BRN 4267656; Bezalip SR; Bezafibrate,(S); Bezafibrate [USAN:INN:BAN:JAN]; PEM; Prestwick_724; BENAFIBRATE; PubChem4066; Spectrum_001443; Opera_ID_376; Prestwick0_000378; Prestwick1_000378; Prestwick2_000378; Prestwick3_000378; Spectrum2_000922; Spectrum3_001500; Spectrum4_000325; Spectrum5_001079; Spectrum5_001967; SCHEMBL16299; Bezafibrate-d6(dimethyl-d6); BSPBio_000535; BSPBio_001314; BSPBio_003119; KBioGR_000034; KBioGR_000669; KBioSS_000034; KBioSS_001923; MLS001148205; Bezafibrate, >=98%, solid; DivK1c_000092; SPECTRUM1502046; SPBio_000824; SPBio_002456; BPBio1_000589; GTPL2668; DTXSID3029869; BDBM28701; Bezafibrate (JP17/USAN/INN); HMS500E14; KBio1_000092; KBio2_000034; KBio2_001923; KBio2_002602; KBio2_004491; KBio2_005170; KBio2_007059; KBio3_000067; KBio3_000068; KBio3_002619; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; NINDS_000092; Bio2_000034; Bio2_000514; HMS1361B16; HMS1569K17; HMS1791B16; HMS1921H16; HMS1989B16; HMS2089F04; HMS2092B12; HMS2096K17; HMS2233E22; HMS3261D21; HMS3369B13; HMS3402B16; HMS3650K22; HMS3652M22; HMS3713K17; Pharmakon1600-01502046; BCP03700; HY-B0637; ZINC3956919; Tox21_110645; Tox21_301845; Tox21_500500; ANW-42342; CCG-39683; NSC758174; s4159; AKOS005107743; Tox21_110645_1; AB03023; AC-6817; BCP9000398; DB01393; HS-0040; LP00500; MCULE-9775992840; NSC 758174; NSC-758174; SB17361; SDCCGSBI-0051715.P003; VA10400; IDI1_000092; IDI1_033784; NCGC00016850-02; NCGC00016850-03; NCGC00016850-04; NCGC00016850-05; NCGC00016850-06; NCGC00016850-07; NCGC00016850-08; NCGC00016850-09; NCGC00016850-10; NCGC00016850-11; NCGC00016850-12; NCGC00016850-15; NCGC00016850-25; NCGC00023317-03; NCGC00023317-04; NCGC00023317-05; NCGC00023317-06; NCGC00023317-07; NCGC00023317-08; NCGC00255376-01; NCGC00261185-01; Bezafibrate, analytical reference material; BCP0726000153; Bezafibrate 100 microg/mL in Acetonitrile; SBI-0051715.P002; 2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy); AB00052265; B3346; FT-0622617; ST51014927; SW196871-4; D01366; K-8763; AB00052265-15; AB00052265_16; AB00052265_17; 859B670; Q577387; SR-01000000106-3; SR-01000000106-4; SR-01000000106-5; W-106291; BRD-K46018455-001-06-0; BRD-K46018455-001-17-7; SR-01000000106-10; Bezafibrate, European Pharmacopoeia (EP) Reference Standard; 2-(4-(2-parachlorobenzamidoethyl)phenoxy)-2-methylpropionic acid; 2-[4-[2-(4-chlorobezamide)ethyl]phenoxy]-2-methylpropanoic acid; 2-(4-{2-[(4-chlorophenyl)carbonylamino]ethyl}phenoxy)-2-methylpropanoic acid; 2-[4-(2-{[(4-chlorophenyl)carbonyl]amino}ethyl)phenoxy]-2-methylpropanoic acid; BF; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl propanoic acid
    Click to Show/Hide
Molecular Type
Small molecule
Disease Hypertriglyceridaemia [ICD-11: 5C80] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H20ClNO4
PubChem CID
39042
Canonical SMILES
CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
InChI
1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
InChIKey
IIBYAHWJQTYFKB-UHFFFAOYSA-N
CAS Number
CAS 41859-67-0
ChEBI ID
CHEBI:47612
TTD Drug ID
D00WCX
DrugBank ID
DB01393
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Ursodeoxycholic acid      Homo sapiens     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 Combination therapy of bezafibrate and UDCA improved biliary enzymes in non-cirrhotic Japanese patients with PBC refractory to UDCA.
Target and Pathway
Target(s) PPAR-alpha (PPARA)  Molecule Info  [3]
KEGG Pathway PPAR signaling pathway Click to Show/Hide
2 cAMP signaling pathway
3 Adipocytokine signaling pathway
4 Glucagon signaling pathway
5 Non-alcoholic fatty liver disease (NAFLD)
6 Hepatitis C
Pathway Interaction Database RXR and RAR heterodimerization with other nuclear receptor Click to Show/Hide
Reactome RORA activates gene expression Click to Show/Hide
2 BMAL1:CLOCK,NPAS2 activates circadian gene expression
3 PPARA activates gene expression
4 YAP1- and WWTR1 (TAZ)-stimulated gene expression
5 Transcriptional activation of mitochondrial biogenesis
6 Activation of gene expression by SREBF (SREBP)
7 Transcriptional regulation of white adipocyte differentiation
8 Nuclear Receptor transcription pathway
9 Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
10 Circadian Clock
WikiPathways Nuclear Receptors in Lipid Metabolism and Toxicity Click to Show/Hide
2 Nuclear Receptors Meta-Pathway
3 Estrogen Receptor Pathway
4 PPAR Alpha Pathway
5 Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
6 Transcriptional Regulation of White Adipocyte Differentiation
7 YAP1- and WWTR1 (TAZ)-stimulated gene expression
8 Activation of Gene Expression by SREBP (SREBF)
9 Adipogenesis
10 SREBF and miR33 in cholesterol and lipid homeostasis
11 Circadian Clock
12 Nuclear Receptors
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2668).
Reference 2 The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008 Jun;38(6):557-64.
Reference 3 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
 Download Picture         KEGG Link